局部益生菌已被建议作为过敏性鼻炎的治疗选择,因为它们可能会使免疫反应偏向有益的1型非过敏性特征。到目前为止,对人类的观察仅涉及口服摄入。这项研究的目的是检查益生菌组合(PA)的局部/鼻腔给药是否会影响生活质量,鼻过敏原攻击(NAC)模型中过敏性鼻炎的症状和体征。
在安慰剂对照和交叉设计中,24例季节性过敏性鼻炎患者随机接受鼠李糖乳杆菌SP1,副干酪乳杆菌101/37和乳酸乳球菌L1A或安慰剂的PA局部/鼻腔给药3周。参与者和研究者对治疗分配视而不见。每个治疗期的最后一周与NAC系列组合。疗效变量为“迷你鼻结膜炎生活质量问卷”(迷你RQLQ),“鼻部症状总评分”(TNSS),“峰值鼻吸气流量”(PNIF)和“呼出气一氧化氮”(FeNO)。此外,评估PA本身是否产生任何促炎作用,在鼻灌洗液中监测可溶性分析物。最后,细菌培养物,使用中鼻道的拭子取样,通过MALDI-TOF分析评估PA的存在。
PA的施用不产生任何鼻部症状(参见安慰剂)。在PA运行中识别出先天性免疫应答(参见基线),但未观察到鼻灌洗液中细胞因子/介质水平的变化。除IL-17/IL-17A外的安慰剂(PA运行略有增加)。PA的管理并不影响Mini-RQLQ,TNSS,PNIF和FeNO。没有观察到持续定殖的证据。
局部/经鼻给药包含鼠李糖乳杆菌SP1、副干酪乳杆菌101/37和乳酸乳球菌L1A的PA,虽然可能会引起轻微的先天免疫反应,但却是安全的,不会影响生活质量,过敏性鼻炎的症状或体征。
未注册。
Topical probiotics have been suggested as a treatment option for allergic rhinitis, as they may skew the immune response towards a beneficial type-1 non-allergic profile. So far observations in man have exclusively involved oral intake. The aim of this
study was to examine whether a topical/nasal administration of a probiotic assemblage (PA) affects quality of life, symptoms and signs of allergic rhinitis in a nasal allergen challenge (NAC) model.
In a placebo-controlled and crossover design, 24 patients with seasonal allergic rhinitis were randomised to topical/nasal administration with a PA of Lactobacillus rhamnosus SP1, Lactobacillus paracasei 101/37 and Lactococcus lactis L1A or placebo for 3 weeks. Participants and investigators were blind to treatment allocation. The last week of each treatment period was combined with a NAC series. Efficacy variables were \"Mini-Rhinoconjunctivitis Quality of Life Questionnaire\" (Mini-RQLQ), \"Total Nasal Symptom Score\" (TNSS), \"Peak Nasal Inspiratory Flow\" (PNIF) and \"Fractional Exhaled Nitric Oxide\" (FeNO). In addition, to assess whether or not the PA produced any pro-inflammatory effect per se, soluble analytes were monitored in nasal lavage fluids. Finally, bacterial cultures, sampled using swabs from the middle nasal meatus, were assessed for the presence of the PA by MALDI-TOF analysis.
Administration of the PA did not produce any nasal symptoms (cf. placebo). An innate immune response was discerned within the PA run (cf. baseline), but no change in nasal lavage fluid levels of cytokines/mediators was observed cf. placebo except for IL-17/IL-17A (a minor increase in the PA run). Administration of the PA did neither affect Mini-RQLQ, TNSS, PNIF nor FeNO. No evidence of persistent colonization was observed.
Topical/nasal administration of a PA comprising Lactobacillus rhamnosus SP1, Lactobacillus paracasei 101/37 and Lactococcus lactis L1A, while likely evoking a minor innate immune response yet being safe, does not affect quality of life, symptoms or signs of allergic rhinitis.
not registered.